secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001193125-25-057153
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec reports positive Phase 1b/2a BB-301 data; three OPMD subjects show durable swallowing improvements
--------------------------------------------------------------------------------

- Subject 1: 41% reduction in total dysphagic symptom burden (SSQ) 12-months post-treatment; VFSS improvements across consistencies.
- Subject 2: 91% reduction in SSQ to 68 units (clinically normal) at 12 months; pathologic sequential swallows dropped from 80% to 17%.
- Subject 3: 68% reduction in SSQ to 70 units (clinically normal) at 3 months; zero pathologic sequential swallows observed.
- No severe adverse events reported; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525057153/0001193125-25-057153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525057153/d820411d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-057153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer